A phase 1 study to investigate the effect of single and repeated doses of DSP-2230/placebo on renal function in healthy subjects

Trial Profile

A phase 1 study to investigate the effect of single and repeated doses of DSP-2230/placebo on renal function in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs DSP 2230 (Primary)
  • Indications Neuropathic pain
  • Focus Pharmacodynamics
  • Sponsors Sunovion Pharmaceuticals Europe
  • Most Recent Events

    • 01 Dec 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 18 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top